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The increased production of amyloid -peptide (A) in Alzhei-
mer’s disease is acknowledged to be a key pathogenic event. In
this study, we examined the response of primary human and rat
brain cortical cultures to A administration and found a marked
increase in the tyrosine phosphorylation content of numerous
neuronal proteins, including tau and putative microtubule-
associated protein 2c (MAP2c). We also found that paired helical
filaments of aggregated and hyperphosphorylated tau are tyrosine
phosphorylated, indicating that changes in the phosphotyrosine
content of cytoplasmic proteins in response to A are potentially
an important process. Increased tyrosine phosphorylation of cy-
toskeletal and other neuronal proteins was specific to fibrillar
A25–35 and A1–42. The tyrosine phosphorylation was blocked by
addition of the Src family tyrosine kinase inhibitor 4-amino-5-(4-
chlorophenyl)-7(t-butyl)pyrazol(3,4-D)pyramide (PP2) and the
phosphatidylinositol 3-kinase inhibitor LY 294002. Tyrosine phos-
phorylation of tau and MAP2c was concomitant with an increase
in the tyrosine phosphorylation and subsequent putative activa-
tion of the non-receptor kinase, focal adhesion kinase (FAK).
Immunoprecipitation of Fyn, a member of the Src family, from
A25–35-treated neurons showed an increased association of
Fyn with FAK. A treatment of cells also stimulated the sus-
tained activation of extracellular regulated kinase-2, which was
blocked by addition of PP2 and LY 294002, suggesting that
FAK/Fyn/PI3-kinase association is upstream of mitogen-
activated protein (MAP) kinase signaling in A-treated neurons.
This cascade of signaling events contains the earliest biochem-
ical changes in neurons to be described in response to A
exposure and may be critical for subsequent neurodegenera-
tive changes.
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Neurofibrillary tangles and senile neuritic plaques with an extra-
cellular core of amyloid are the pathological lesions in the brain
in Alzheimer’s disease (Smith and Anderton, 1994). Although
deposition of amyloid -peptide (A) is an early event as Alz-
heimer’s disease (AD) develops, it is not clear how tangles sub-
sequently form. Neurofibrillary tangles are composed of paired
helical filaments of aggregated and hyperphosphorylated tau
(PHF-tau) (Lovestone et al., 1994; Hanger et al., 1998). Several
laboratories have reported that A treatment of neurons in pri-
mary culture results in an elevation in tau phosphorylation, in-
dicative of a link between A deposition and tau pathology
(Busciglio et al., 1995).
In these previous studies, changes in the phosphorylation state
of tau were usually observed after prolonged exposure to A. The
protein kinases implicated in phosphorylating tau in response to
A treatment include the extracellular regulated kinase-1
(ERK1) and ERK2 (McDonald et al., 1998; Pyo et al., 1998;
Rapoport and Ferreira, 2000), cyclin-dependent kinase-5 (Ima-
hori and Uchida, 1997; A. Alvarez et al., 1999; Lee et al., 2000),
and glycogen synthase kinase-3 and -3 (GSK-3 and -3)
(Takashima et al., 1998). Other studies of the effects of A on
cells have shown that certain parameters are affected within
shorter periods. These include activation of the protein tyrosine
kinase (PTK) Lyn in microglial cells (McDonald et al., 1998),
increased tyrosine phosphorylation and Ca2 influx (Luo et al.,
1995), activation of phosphatidylinositol 3-kinase (PI3-kinase)
(Luo et al., 1996), cAMP response element-binding protein phos-
phorylation (Sato et al., 1997), increased oxidative stress (Ekinci
et al., 2000), and finally apoptosis (Harada and Sugimoto, 1999).
The tyrosine kinase Fyn is upregulated in a subset of neurons
in AD brain that also contain hyperphosphorylated tau (Shirazi
and Wood, 1993). Fyn knock-out mice display specific neurolog-
ical deficits (Grant et al., 1992), and brain slices from Fyn knock-
out mice are completely protected from A-derived diffusible
ligand (ADDL) toxicity (Lambert et al., 1998). Fyn is associated
with tyrosine phosphorylated tau in neuronal cells, and Fyn may
activate the serine/threonine kinase, GSK-3, a tau kinase that
can hyperphosphorylate tau (Lee et al., 1998; Lesort et al., 1999).
Here we report that treatment of primary human and rat
cortical neuronal cultures with fibrillar A resulted in a rapid
increase in the overall tyrosine phosphorylation of several cellular
proteins, including tau and most probably the microtubule-
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associated protein 2c (MAP2c). The increased tyrosine phosphor-
ylation was specific to treatment with aggregated A and was
blocked by addition of the Src family tyrosine kinase inhibitor
4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazol(3,4-D)pyramide
(PP2). Increased phosphorylation of focal adhesion kinase (FAK)
on tyrosine was also observed after A treatment, and immuno-
precipitation of Fyn from A-treated neurons showed an increase
in association of Fyn with FAK. Concomitant with these rapid
changes in tyrosine phosphorylation of cellular proteins, A
treatment also activated ERK2. The rapid changes in FAK/Fyn
and tau tyrosine phosphorylation reported here may be critical
early pathogenic events initiated by A. Furthermore, because the
tyrosine phosphorylation changes preceded neuronal death by
many hours, A stimulation of these signaling events is likely to
be a rapid event but with long-term effects.
MATERIALS AND METHODS
All chemicals were purchased from Sigma (Gillingham, UK), unless
otherwise stated. The Src family kinase inhibitor PP2, the PI3-kinase
inhibitors wortmannin and LY 294002, and the MEK activation inhibitor
PD 98059 were obtained from Calbiochem (Nottingham, UK). The
A-derived peptide comprising amino acids 25–35 (A25–35), the reverse
sequence 35–25 (A35–25), and 1–42 (A1–42) were obtained from
Bachem (Essex, UK). A25–35 and A35–25 were resuspended in sterile
distilled H2O at a concentration of 2 mM and incubated at 37°C for 1 hr
to allow fibril formation (Terzi et al., 1994). A1–42 was resuspended in
50% (v/v) PBS/sterile distilled H2O at a concentration of 1.5 mg/ml and
incubated at 37°C for 7 d to allow fibril formation (Serpell, 2000). Soluble
A25–35 was prepared immediately before use by resuspending A25–35 in
sterile H2O at a concentration of 1 mg/ml. Anti-phospho-ERK mono-
clonal antibody (mAb) was obtained from New England Biolabs (Hitchin,
UK). Anti-ERK polyclonal antibody (pAb) and anti-Fyn mAb were
obtained from Transduction Laboratories (Lexington, KY). Anti-
MAP2c mAb HM-2 was obtained from Sigma. Anti-phosphotyrosine
mAb 4G10 was obtained from Upstate Biotechnology (Lake Placid, NY).
Anti-FAK pAb C20 was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Protein A/G Plus was obtained from Autogen Bioclear
(Wiltshire, UK). mAb PHF-1 was provided by Dr. P. Davies (Depart-
ment of Pathology, Albert Einstein College of Medicine, Bronx, NY).
SHP-1 tyrosine phosphatase was cloned and expressed by one of our
collaborating laboratories. Horseradish peroxidase (HRP)-conjugated
donkey anti-rabbit and sheep anti-mouse Igs were obtained from Amer-
sham Pharmacia (Buckinghamshire, UK).
Primary cortical neuronal cultures. Neuronal cultures were prepared
from embryonic day 18 rat embryos as described previously (Davis et al.,
1995). Essentially, embryos were removed, and their fetal brain cortices
were dissected and freed of meninges. The cells were dissociated by
trypsinization [0.25% (v/v) for 20 min at 37°C]. Trypsinization was
stopped by washing three times in Neurobasal medium (Life Technolo-
gies, Paisley, UK) containing 10% (v/v) fetal calf serum (FCS) (Autogen
Bioclear) and then treated with 2 Kunitz U/ml deoxyribonuclease 1
followed by trituration with fire-polished Pasteur pipettes. Primary rat
brain cortical cells (2  10 5) were plated onto poly-L-lysine (10 g/ml)-
coated glass coverslips in 12-well tissue culture plates, or 4 10 6 neurons
were plated into 25 cm 2 flasks (Marathon, Harrow, UK) and maintained
in Neurobasal medium containing B27 supplement (Life Technologies),
2 mM glutamine, and 20 g/ml gentamycin solution. Rat brain primary
cells were cultured for 7 d before being used for the treatments described.
Primary human brain neuronal cultures were established from termina-
tions of pregnancy at 14–20 week gestation through collaboration with
King’s College Hospital, Ethical Committee approval No. 1997–0037.
Brain cortices were identified on the basis of their large size and
presence of convolutions (immature gyri). Cell dissociation and culture
procedures were essentially identical for rat and human tissue except that
human cells were plated onto poly-L-lysine (10 g/ml)-coated and lami-
nin (5 g/ml)-coated glass coverslips in 12-well tissue culture plates or
into 25 cm 2 flasks. Cells were cultured for 14 d to allow them to attain a
fully polarized and mature phenotype similar to 7-d-old rat brain pri-
mary cells (our unpublished observations), with a change of medium
every third day before they were used for the treatments described.
Cell treatments. Cells were treated with the appropriate peptide for the
indicated times in culture medium. In some instances cells were pre-
treated with 30 M PP2 for 18 hr, 20 M PD 98059 for 45 min, 100 M LY
294002 for 15 min, 100 nM wortmannin for 15 min, 10 M bis-
indolylmaleimide for 45 min, or 25 mM LiCl for 4 hr.
Enrichment of PHF-tau from AD brain. Gray matter from an AD brain
was obtained from The London Neurodegenerative Diseases Brain Bank
(Department of Neuropathology, Institute of Psychiatry) and hand-
homogenized in a glass Dounce homogenizer in ice-cold Buffer A [100
mM 2-(morpholino)ethanesulfonic acid (MES), pH 6.5, 0.5 mM MgCl2, 1
mM EGTA, 1 M NaCl, 50 mM D-N-acetylglucosamine, 50 mM imidazole,
25 mM -glycerophosphate, 20 mM NaF, 10 mM Na pyrophosphate, and
0.5 mM PMSF], using 4 ml Buffer A per gram of tissue. Insoluble material
was removed from the homogenate by centrifugation at 27,000  g
(average) at 4°C for 30 min. The pellet was discarded, and the superna-
tant was centrifuged at 95,000 g at 4°C for 2 hr. The resulting pellet was
resuspended in Buffer B (10 mM Tris-HCl, pH 7.4, 4 M guanidine-HCl,
10 mM DTT, 50 mM D-N-acetylglucosamine, 50 mM imidazole, 25 mM
-glycerophosphate, 20 mM NaF, 10 mM Na pyrophosphate, and 0.5 mM
PMSF), using 0.5 ml Buffer B per gram of starting material for 2 hr at
room temperature. The resulting suspension was centrifuged at 95,000 
g (average) at 4°C for 1 hr. The supernatant was retained and dialyzed
overnight at 4°C against 8 l of Buffer C (20 mM bis-Tris-propane, pH 7.0,
and 1 mM DTT) before centrifugation at 95,000  g (average) at 4°C for
1 hr. The resultant supernatant was boiled for 10 min, then cooled on ice
and centrifuged at 95,000  g (average) at 4°C for 1 hr. The final
supernatant was used for SDS-PAGE and Western blotting.
Western blotting, tyrosine phosphatase treatment, and immunoprecipita-
tions. Cells were washed three times in ice-cold TBS (25 mM Tris, pH 8.0,
140 mM NaCl, and 5 mM KCl) and lysed by scraping into ice-cold
radioimmunoprecipitation assay (RIPA) buffer [1% (v/v) Triton, 0.1%
(w/v) SDS, 0.5% (w/v) deoxycholate, 20 mM Tris, pH 7.4, 150 mM NaCl,
10 mM NaF, 1 mM Na3VO4, 1 mM EDTA, 1 mM EGTA, and 0.2 mM
PMSF] and left to stand for 20 min on ice. Insoluble material was
removed by centrifugation at 15,800  g (average) at 4°C for 10 min.
Heat-stable fractions were prepared by scraping cells into ice-cold TBS
and centrifuging at 15,800  g (average) at 4°C for 10 min. The super-
natant was discarded, and the pellet was resuspended in 100 l MES/
NaCl buffer (100 mM MES, 1 M NaCl, 0.5 mM MgCl2, 1 mM EGTA, 2 mM
DTT, 1 mM Na3VO4, 1 mM benzamidine hydrochloride, 5 g/ml leupep-
tin, 2 g/ml aprotinin, 1 g/ml pepstatin, 0.2 mM PMSF) and immedi-
ately heated to 100°C for 10 min followed by cooling by immersing in ice
and then centrifuged at 15,800  g (average) at 4°C for 25 min. The
supernatant that was enriched in tau and MAP2c was retained. Protein
concentrations were quantified by the method of Bradford (1976). Before
electrophoresis, samples were mixed with equal volumes of 2 SDS-
PAGE sample buffer (Sigma), heated to 100°C for 5 min, and then
centrifuged at 15,800  g (average) for 5 min. Proteins were resolved by
SDS-PAGE using 10% (w/v) polyacrylamide. Proteins were transferred
to nitrocellulose (Schleicher & Scheull, Dassel, Germany) and sub-
merged in blocking buffer TBS-Tween [TBS containing 0.2% (v/v)
Tween 20 and 3% (w/v) nonfat dried milk] for 1 hr at room temperature.
Blots were incubated with primary antibody diluted in blocking buffer
overnight at 4°C. Blots were washed three times in PBS-Tween and
incubated with HRP-linked secondary antibodies diluted in blocking
buffer for 1 hr. After an additional three washes in TBS-Tween, antibody
binding was detected by an enhanced chemiluminescence (ECL) system
(Amersham Pharmacia).
For phosphotyrosine antibody detection, blocking buffer and primary
antibody buffer contained 4% (w/v) BSA instead of 3% (w/v) nonfat
dried milk. To reprobe blots, nitrocellulose was stripped by washing in
100 mM 2-mercaptoethanol, 2% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.7,
for 30 min at 50°C with occasional agitation. For tyrosine phosphatase
treatment, total cell lysates from primary cortical cultures were resolved
by SDS-PAGE followed by transfer of proteins to nitrocellulose and
subsequent blocking in blocking buffer for 1 hr at room temperature.
Blots were then incubated for 2 hr in 0.1% (v/v) 2-mercaptoethanol, 50
mM Tris-HCl, pH 6.7, containing 8.6 g/ml His-tagged full-length SHP-1
for 2 hr at room temperature with occasional agitation.
Immunoprecipitations were performed by incubation of cell lysates
(400 g total protein) with 1 g primary antibody for 2 hr at 4°C followed
by addition of 20 l protein A/G PLUS-Agarose and a further incubation
of 1.5 hr at 4°C. The mixture was then centrifuged at 15,800  g
(average) at 4°C for 5 min, and the supernatant was removed at 4°C until
analysis. The beads were washed four times in ice-cold RIPA buffer.
After the final wash, the beads were resuspended in 40 l SDS-PAGE
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sample buffer, heated to 100°C for 10 min, resolved by 7.5% (w/v)
polyacrylamide SDS-PAGE, and Western blotted as described above.
Characterization of tyrosine phosphorylated tau antibody. The pAb
121–3 was raised in rabbit to a synthetic tyrosine phosphorylated peptide
of tau corresponding to residues 21–36 of human tau [largest isoform
with two N-terminal inserts and four C-terminal repeats (2N4R)] and so
recognizes tau when it is phosphorylated at Tyr29. The specificity of the
121–3 antibody was tested on 2N4R recombinant tau that was either
unphosphorylated or phosphorylated on tyrosine residues as follows: 5 l
(24 g) of 2N4R recombinant tau was added to 51 l reaction mixture
(50 mM Tris-HCl, pH 7.5, 1 mM ATP, 10 mM MgCl2, 5 mM MnCl2, 0.1
mM EDTA, 10 M Na3VO4, and 1 mM DTT) and incubated in the
presence (for phosphorylation) or absence (control, unphosphorylated)
of 4 l lck at 30°C for 2 hr. The reaction was stopped by addition of 2
SDS-PAGE sample buffer and heating to 100°C for 5 min. Unphosphor-
ylated or phosphorylated tau (0.4 g) was resolved by SDS-PAGE using
10% (w/v) polyacrylamide, transferred to nitrocellulose, and probed with
antibodies TP70, 4G10, and 121–3 as described previously. Figure 1
shows that both the 4G10 and 121–3 antibodies were specific for the
tyrosine-phosphorylated tau and did not react with tau that was not
phosphorylated. The phosphorylated tau displays a slightly reduced
electrophoretic mobility compared with the unphosphorylated tau as
detected by TP70 because of its increased phosphorylation. The lck band
is labeled by the 4G10 antibody because of autophosphorylation.
Immunofluorescence microscopy. Cultures were fixed in 4% (w/v) para-
formaldehyde (PFA) for 30 min at room temperature, permeablized with
0.2% (v/v) Triton X-100 in TBS for 10 min, and blocked in 5% (v/v)
FCS/0.2% (w/v) Tween 20 in TBS for 30 min. Primary antibody was
diluted in blocking solution and incubated for 1 hr. FAK and Fyn were
detected by a monoclonal antibody to Fyn, referred to here as anti-Fyn,
and by C-20, a polyclonal antibody to FAK. Primary antibodies were
detected using goat anti-mouse or goat anti-rabbit Igs coupled to Oregon
Green or Texas Red (Molecular Probes, Eugene, OR), and the slides
were mounted in Vectashield (Vector Labs, Burlingame, CA). Cells were
analyzed using a Zeiss Axioscop microscope at 40 magnification, and
images were captured via a CCD camera (Princeton Instruments, Mar-
low, UK).
Caspase activation. Caspase activation was measured using a
CASPATAG kit (Intergen Company, Oxford, UK) comprising a car-
boxyfluorescein (FAM) derivative of benzyloxycarbonylvalylalany-
laspartic acid fluoromethyl ketone (zVAD-FMK), which is a potent
inhibitor of the caspase activity. The FAM-VAD-FMK binds irreversibly
to activated caspase-1,-3,-4,-5,-7,-8. FAM-VAD-FMK was added to the
neuronal cultures and incubated at 37°C for 1 hr. Hoechst stain (200
g/ml) was added (1:500 dilution) for 5 min, and the cells were washed
twice in TBS and fixed in 4% (w/v) PFA for 30 min at room temperature;
the slides were mounted in Vectashield.
Cell viabilit y. Primary rat neuronal cells were cultured in 96-well tissue
culture plates and grown for 7 d. After 7 d in culture, media was replaced,
and the cells were treated with A peptides. Lactate dehydrogenase
(LDH) release was assayed using the Cytotox 96 assay kit (Promega UK
Ltd., Southampton, UK). Total LDH release was determined by treat-
ment of cultures with 0.9% (v/v) Triton X-100 for 45 min. Fifty micro-
liters from each well were transferred to a 96-well plate and mixed with
50 l substrate mix. After 30 min incubation at room temperature, the
reaction was stopped by adding 50 l stop solution. Absorbance was read
at 492 nm using a Bio-Tek microplate reader.
Densitometry and image analysis. Film images from ECL-developed
Western blots developed for different times to ensure linearity of
exposure were analyzed with a GS710 scanning densitometer using the
Quantity One (Bio-Rad, Hemel Hempstead, UK) quantification
software.
RESULTS
A activates caspases during the neurotoxic response
of rat and human fetal brain neurons
To establish conditions of A neurotoxicity, A25–35 was aged to
produce aggregated A25–35 and applied to rat or human primary
neuronal cultures in Neurobasal medium either with or without
supplements. Cells were stained for activated caspases after ex-
posure to A25–35 for different times, and cell lysis was monitored
by release of LDH. Typical results after different exposure times
to A are illustrated in Figure 2. The earliest time at which
caspase activation and LDH release could be observed was 24
hr and was maximal at 96 hr. The 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, in-
ner salt (MTS) assay was also used to monitor neurotoxicity and
showed a reduction of 30% of the ability of the cells to reduce
MTS after 24 hr of A25–35 treatment and was complete at 72 hr
(data not shown). The reverse sequence A35–25 induced no
detectable cell death by the LDH or MTS assays, and the pres-
ence or absence of B27 supplement did not affect the neurotoxic
response. All subsequent experiments were thereafter performed
in Neurobasal medium supplemented with B27.
Figure 1. Characterization of tyrosine-phosphorylated tau-specific anti-
body 121–3. Western blots of 2N4R recombinant tau that was either
unphosphorylated () or phosphorylated () by lck were probed with the
antibodies TP70, 121–3, and 4G10 as indicated. Arrowhead indicates the
tau band; arrow indicates the lck band.
Figure 2. A-induced neuronal death of primary rat cortical cultures. A,
B, Hoechst nuclear labeling and immunolabeling (C, D) of activated
caspases in untreated control cultures (A, C) and A25–35-treated cultures
(10 M, 48 hr) (B, D) of 7-d-old primary rat cortical cultures. Scale bars,
50 M. E, LDH release from control () cultures and cultures treated (f)
with A25–35 (10 M; 24 hr, 48 hr, 72 hr, 96 hr), expressed as fold increase
in LDH release over control LDH release after 24 hr, normalized to 1.
Error bars indicate SDs based on three independent experiments, 15
readings per experiment. *p  0.0001; Mann–Whitney U test.
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A treatment induces a rapid elevation of tyrosine
phosphorylation of numerous neuronal proteins
To identify possible early cellular responses to A treatment that
precede measurable cell death, changes in phosphotyrosine con-
tent of neuronal proteins were investigated because tyrosine
phosphorylation is often an early signaling event. Total cell ly-
sates analyzed by Western blotting with the phosphotyrosine-
specific monoclonal antibody 4G10 showed that exposure of rat
neuronal cultures to A25–35 resulted in a rapid increase in the
phosphotyrosine content of numerous proteins (Fig. 3A). There
was an increase in the tyrosine phosphorylation content of at least
eight bands ranging between relative molecular masses of 38 and
120 kDa. The increase in phosphotyrosine content of all of these
proteins was already very marked after 1 min exposure to A25–35
but was partially transient, peaking at 2 min after exposure and
declining thereafter.
Similar patterns of changes were obtained for total cell lysates
of A-treated primary human brain cortical cultures (Fig. 3B).
There was an increase in tyrosine phosphorylation of approxi-
mately seven or eight bands. Again, the increase in the phospho-
tyrosine content of most of these proteins was marked after 1 min
A treatment and peaked at 2 min after exposure. However,
unlike the primary rat cortical cultures, the phosphotyrosine
content of these proteins had declined to control untreated levels
by 10 min after exposure. Treatment of primary rat neuronal
cultures with soluble A25–35 did not result in an increase in the
phosphotyrosine content of any proteins (data not shown).
Exposure of rat neuronal cultures to the full-length fibrillar A
peptide, A1–42, also resulted in an increase in the phosphoty-
rosine content of neuronal proteins, although in this experiment
the peak was somewhat delayed to 5 min, and the increase in
phosphotyrosine content was less marked than in A25–35-treated
cultures (Fig. 4A). Tyrosine phosphatase treatment of the blot
with SHP-1 completely abolished the 4G10 signals for both con-
trol and A1–42-treated samples (Fig. 4B). Subsequent stripping
and reprobing of the blot with the mAb PHF-1, which detects tau
phosphorylated at its serine 396 and serine 404 residues, revealed
a band at 56 kDa (Fig. 4C). This confirmed that the 4G10
immunoreactivity reflected neuronal protein tyrosine phosphor-
ylation and was not caused by protein phosphorylation on other
residues or nonspecific reactivity. Figure 4D shows an identically
loaded Coomassie-stained gel, demonstrating equal protein
loading.
To identify some of the proteins that exhibited increased ty-
rosine phosphorylation, heat-stable fractions from the cultures
were analyzed because selected proteins are easily enriched by
heat treatment, including tau, which is important in Alzheimer’s
disease and has previously been shown to be tyrosine phosphor-
ylated under certain experimental conditions (Lee et al., 1998).
Western blots with 4G10 of heat-stable fractions from control and
A25–35-treated rat and human primary neuronal cultures re-
sulted in very similar patterns of labeled proteins (Fig. 5A).
Control cultures had essentially a single strong band of apparent
molecular mass 77 kDa, with weakly labeled material of slightly
lower mobility (lanes 1 and 4). A25–35 treatment of both rat and
Figure 3. A-induced tyrosine phosphorylation of neuronal proteins.
Rat primary cortical neurons (A) (7 d in culture) and human primary
cortical neurons (B) (14 d in culture) were treated with 10 M A25–35 as
follows: lane 1, control (no A25–35); lane 2, 1 min; lane 3, 2 min; lane 4,
5 min; lane 5, 10 min. Whole-cell lysates were prepared, and Western blots
were probed with anti-phosphotyrosine antibody 4G10. Apparent molec-
ular mass (kDa) markers are indicated to the lef t.
Figure 4. Full-length A induces tyrosine phosphorylation of neuronal
proteins. Rat primary cortical neurons (7 d in culture) were treated with
10 M A1–42 as follows: lane 1, control (no A1–42); lane 2, 1 min; lane 3,
2 min; lane 4, 5 min; lane 5, 10 min. A, Whole-cell lysates were prepared,
and the Western blot was probed with anti-phosphotyrosine antibody
4G10. B, An identically loaded gel was blotted and subsequently treated
with SHP-1 protein tyrosine phosphatase before probing with anti-
phosphotyrosine antibody 4G10. C, Blot from B was stripped and re-
probed with mAb PHF-1. D, An identically loaded Coomassie-stained gel.
Apparent molecular mass (kDa) markers are indicated to the lef t.
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human cultures resulted in a marked increase in intensity of
labeling of this 77 kDa band and the appearance of a second band
at 58 kDa (lanes 2 and 5). A25–35 treatment of human but not
rat neurons also resulted in the appearance of a band at 29 kDa
(lane 5). These were the only 4G10-immunoreactive species re-
producibly observed in the heat-stable fractions from the cultures.
4G10 Western blots of the reverse sequence A35–25-treated
cultures were indistinguishable from control cultures, demon-
strating that the response was specific for the neurotoxic peptide
(rat cultures treated with A35–25, lane 3; treatment of human
cells with A35–25 not shown). Similar results were obtained using
the polyclonal antibody PY20, which also detects phosphotyrosine
residues (data not shown).
Western blots of the heat-stable fractions were probed with
monoclonal antibody to MAP2, HM-2, and the polyclonal anti-
body to tau, TP70. The 77 kDa species was labeled by HM-2 (Fig.
5A, lane 6), suggesting that this material is most likely MAP2c,
and the 58 kDa species was labeled by TP70, again suggesting that
it is tau (Fig. 5A, lane 7). TP70 was raised against a synthetic
C-terminal peptide of tau that shares sequence homology with
the C terminus of MAP2c and has previously been shown to
recognize both tau and MAP2c (Brion et al., 1993a), hence the
labeling of both bands by TP70 in Figure 5A (lane 7). Thus, the
fact that this 77 kDa species is heat stable and labeled by two
antibodies that recognize MAP2c strongly suggests that it is
identical with MAP2c, although we cannot formally rule out
another phosphotyrosine-containing protein comigrating at this
point. Densitometric analysis of the Western blots showed that
A treatment gave maximum increases in the phosphotyrosine
content of approximately fivefold for the putative MAP2c and
fourfold for tau.
To confirm that the increase in phosphotyrosine content of the
58 kDa species is indeed caused by an increase in phosphoty-
rosine content of tau, Western blots of total cell lysates from
control untreated and A-treated primary human brain cortical
cultures were probed with the phosphotyrosine tau-specific pAb
121–3, which revealed that the increase in the phosphotyrosine
labeling of the 58 kDa species was caused by an increased phos-
photyrosine content of tau (Fig. 5B). The response in this ex-
periment was both rapid and transient, peaking at 1 min after
exposure. The increase in tyrosine phosphorylation of tau was
specific to A treatment and was not caused by an increase in
the overall levels of tau as demonstrated by TP70 labeling (Fig.
5C). Thus, the increase in labeling by 4G10 of the band migrat-
ing in the position of tau is clearly attributable to a genuine
increase in the phosphotyrosine content of tau and not to some
other protein comigrating with tau, because the polyclonal anti-
body 121–3 is specific to phosphorylated tyrosine 29 within the
human tau sequence.
Src family PTKs are involved in A-induced increases
in protein phosphotyrosine content
The compound PP2 inhibits members of the Src family of PTKs
such as Src and Fyn. Cultures of primary rat neurons were
pretreated with 10 M PP2 for 18 hr before exposure to A25–35,
and heat-stable proteins were probed with 4G10. Figure 5D shows
that PP2 pretreatment completely prevented the rapid increase in
phosphotyrosine content of tau and putative MAP2c in response
to exposure to A25–35 (lanes 1 and 3). It is also apparent that
pretreatment of cultures with PP2 reduces the basal levels of
tyrosine phosphorylation of both cytoskeletal proteins (compare
lane 3 with lane 1). Pretreatment of these rat cortical cultures with
the protein kinase C (PKC) inhibitor bis-indolylmaleimide before
treatment with A25–35 had no effect on the phosphotyrosine
content of tau and putative MAP2c (compare lane 2 with lane 4).
However, pretreatment with wortmannin, which selectively inhib-
its PI3-kinase, before treatment with A25–35 essentially abol-
ished the increase in phosphotyrosine content of both cytoskel-
etal proteins induced by A25–35 treatment (compare lanes 1, 2,
and 5). The effects are most noticeable for tau because the blots
are overexposed to detect changes in tau labeling, and hence
changes in the putative MAP2c are less obvious.
PHF-tau is tyrosine phosphorylated
Because A treatment of neurons in culture clearly resulted in an
increase in tyrosine phosphorylation of tau, we reexamined PHF-
Figure 5. A-induced tyrosine phosphorylation of cytoskeletal proteins.
A, Heat-stable extracts of 7-d-old rat and 14-d-old human primary neu-
ronal cultures were prepared after treatments as described below and
probed with 4G10 (lanes 1–5). Lanes 1–3, Rat primary neuronal cultures
(7 d in culture) were either untreated (lane 1, untreated control) or treated
for 5 min with 10 M A25–35 (lane 2) or with 10 M A35–25 (lane 3,
reverse-sequence control). Lanes 4–5, Human primary cultures (14 d in
culture) were either untreated (lane 4 ) or treated for 5 min with 10 M
A25–35 (lane 5). Untreated control rat lysates were also probed with the
anti-MAP2 antibody HM-2 (lane 6 ) or the anti-tau antibody TP70, which
also reacts with MAP2c as well as with tau (lane 7 ). B, C, Western blots
of total cell lysates from 14-d-old human primary cortical cultures treated
with 10 M A25–35 as follows: lane 1, untreated control; lane 2, 1 min; lane
3, 2 min; lane 4, 5 min; lane 5, 10 min. B was probed with the polyclonal
antibody 121–3 specific to tau in which tyrosine 29 is phosphorylated; C
was probed with the polyclonal antibody TP70 to total tau. D, Western
blot with 4G10 of heat-stable preparations from control 7-d-old primary
rat brain cortical cultures (lane 1) or cultures treated with A25–35 alone
for 5 min (lane 2), A25–35 for 5 min in culture pretreated with the
Src-family kinase inhibitor PP2 (lane 3), A25–35 for 5 min in culture
pretreated with the protein kinase C inhibitor bis-indolylmaleimide (lane
4 ), and A25–35 for 5 min in culture pretreated with the PI3-kinase
inhibitor wortmannin for 15 min (lane 5). Apparent molecular mass (kDa)
markers are indicated to the lef t. Bands labeled MAP2c and tau in A had
an interpolated molecular mass of 77 and 58 kDa, respectively.
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tau isolated from AD brain for evidence of tyrosine phosphory-
lation. Partially purified PHF-tau from selected cases was labeled
on Western blots by 4G10 in a pattern that was identical to
labeling with the polyclonal tau antibody TP70 and monoclonal
antibody PHF-1 (Fig. 6A). The labeling by 4G10 was weaker than
PHF-1, and it was found to be necessary to enrich for PHF-tau to
observe clear labeling by 4G10, suggesting that the phosphoty-
rosine content is lower than the level of phosphorylation at the
PHF-1 epitope (serines 396 and 404) (Otvos et al., 1994). Figure
6B confirms that the labeling of PHF-tau by 4G10 is the result of
a portion of PHF-tau containing tyrosine in a phosphorylated
state because at least two of the PHF-tau bands were labeled by
pAb 121–3. The difference in pattern between 4G10 and pAb
121–3 may be because not all species of PHF-tau contain the same
levels of Tyr29 in a phosphorylated state and the tyrosine residues
probably also exist in a dephosphorylated state.
Furthermore, tau extracted from neurologically unimpaired
individuals is not labeled by the pAb 121–3. We have not ob-
served labeling of tau from control postmortem human brain by
4G10, and we were unable to label adult rat brain tau with 4G10,
even after the brain was immediately immersed in liquid nitrogen
and the tau extracted in buffers containing phosphatase inhibi-
tors. However, tau from neuronal cultures, which is equivalent to
fetal brain tau, is weakly labeled by 4G10 (Fig. 5D, lane 1).
A induces association of FAK with Fyn and increased
tyrosine phosphorylation of FAK
Because A is applied externally to neurons in paradigms of A
neurotoxicity, it is reasonable to assume that it stimulates intra-
cellular PTKs via a plasma membrane receptor and signaling
complex. It has previously been reported that A treatment of a
neuroblastoma cell line (rat CNS B103 neuroblastoma cells)
resulted in an increased level of FAK tyrosine phosphorylation,
but only after 48 hr of A treatment (Zhang et al., 1994). A
related non-receptor tyrosine kinase PYK2 has also been re-
ported to phosphorylate tyrosine on proteins in response to A in
microglial cells (Combs et al., 1999). Because PP2, an inhibitor of
the Src family of non-receptor tyrosine kinases, blocked A-
induced tyrosine phosphorylation of tau and the putative MAP2c
(Fig. 5D), we investigated the potential involvement of FAK,
PYK2, Fyn, and Src in the rapid changes in neuronal protein
phosphotyrosine content.
Double-immunofluorescent labeling showed that primary rat
neuronal cultures express both FAK and Fyn and that both FAK
and Fyn can be found in the same neuronal compartments, i.e.,
perikarya and the neuritic network (Fig. 7A,B). Total cell lysates
of primary rat cortical cultures contained both Src and Fyn, and
the levels of these proteins as assessed by Western blot of total
cell lysates did not change after exposure to A (data not shown).
Neurons were left untreated or were exposed to A25–35 or the
reverse sequence A35–25 and harvested at different times after
exposure in RIPA buffer. Proteins were immunoprecipitated with
polyclonal antibodies to either Fyn or Src. The immunoprecipi-
Figure 6. PHF-tau is tyrosine phosphorylated. A, Western blots of par-
tially purified PHF-tau isolated from AD brain probed with TP70 (lane
1), PHF-1 (lane 2), 4G10 (lane 3). B, Western blot of tau extracted from
a control (non-AD brain; lanes 1 and 3) and an AD brain (lanes 2 and 4 )
probed with polyclonal antibody 121–3 (lanes 1 and 2) and with TP70 (lane
3 and 4 ). Apparent molecular mass (kDa) marker is indicated to the lef t.
Figure 7. A induces FAK/Fyn association with increased tyrosine
phosphorylation of FAK. Double immunolabeling of 7-d-old primary rat
brain cortical cultures with the polyclonal antibody FAK (A) and the
monoclonal antibody to Fyn ( B). Scale bars, 50 M. C–E, Western blots of
protein lysates immunoprecipitated with anti-Fyn polyclonal antibody
from control 7-d-old primary rat cortical cultures (lane 1) and cultures
treated with A25–35 (10 M) for 1 min (lane 2), 2 min (lane 3), 5 min (lane
4 ), 10 min (lane 5), or treated with A35–25 (10 M) for 5 min (lane 6 ). C
was probed with the polyclonal antibody Fyn. D was probed with the
polyclonal antibody FAK. E was probed with the monoclonal antibody
4G10 to phosphotyrosine. Apparent molecular mass (kDa) is indicated on
the lef t.
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tates were probed on Western blots using 4G10 or antibodies to
FAK, Fyn, or Src. There was no difference in the amount of Fyn
immunoprecipitated after the different treatments (Fig. 7C), and
it was found that FAK in control neurons (untreated) coprecipi-
tated with Fyn, and exposure to A25–35 resulted in an increase in
the amount of FAK associated with Fyn (Fig. 7D). The FAK that
was complexed with Fyn from untreated neurons was very weakly
tyrosine phosphorylated, but exposure of neurons to A25–35
resulted in a marked increase in phosphotyrosine content of
FAK, indicative of an activation of FAK (Fig. 7E). The reverse
sequence A35–25 did not result in a similar activation of FAK
(Fig. 7E, lane 6). No association between Src and FAK was
observed in either untreated or treated cells (data not shown),
and no evidence for the expression of PYK2 was found in our
neuronal cultures (data not shown). Kinase assays of Fyn immu-
noprecipitated from A25–35-treated primary neuronal cultures
revealed a high level of kinase activity in both A25–35-treated
and control untreated cultures, suggesting that A treatment does
not result in an increase in activation of total Fyn kinase; rather
it results in a relocalization of active Fyn to FAK.
The above experiments showed that the FAK that is associated
with Fyn is also tyrosine phosphorylated specifically in response
to A25–35 treatment. To determine whether the increased ty-
rosine phosphorylation of FAK represented a significant fraction
of the total cellular FAK, immunoprecipitation of FAK from both
rat and human neuronal cultures was performed. Figure 8, A and
B, show that indeed there was a marked increase in tyrosine
phosphorylation of total cellular FAK in response to A25–35
treatment of rat and human neurons, respectively. The kinetics of
FAK activation appeared to be similar in rat and human neurons,
although there was apparently a slightly longer delay to peak
activation in human neurons (Fig. 8B) compared with rat (Fig.
8A). The peak level of 4G10 labeling indicated a four- to fivefold
increase in FAK tyrosine phosphorylation in both rat and human
neurons. The levels of immunoprecipitated FAK protein re-
mained constant during the course of A25–35 exposure (data not
shown). The increased tyrosine phosphorylation of FAK was also
observed after treatment of rat neurons with full-length A1–42
(Fig. 8C), and thus, like the increase in content of phosphoty-
rosine of numerous neuronal proteins (Fig. 3), the signaling
responses are also not restricted to the shorter neurotoxic
peptide.
A-induced FAK activation involves PI3-kinase and
Fyn but not PKC
Cellular responses of neurons to A treatment have implicated
activation of a number of protein kinases. Physiological levels of
A (1 nM) have been reported to activate PI3-kinase through a
tyrosine signaling cascade (Luo et al., 1996). A has also been
found to activate the MAP kinase pathway, and lithium has been
shown to protect against the toxic effect of A, which indicates
the involvement of GSK-3 in cell death (Luo et al., 1997; G.
Alvarez et al., 1999; Wei et al., 2000). To determine which, if any,
of these pathways acts on FAK tyrosine phosphorylation, the
cultures were either left untreated or pretreated with LY 294002,
PD 98059, bis-indolylmaleimide, lithium chloride, or PP2 before
exposure to A25–35 for 5 min. The cells were then lysed on ice in
RIPA buffer, and the lysates were immunoprecipitated with the
polyclonal antibody anti-FAK. Immunoprecipitates were sepa-
rated by SDS-PAGE and probed on Western blots using the
monoclonal antibody 4G10, to detect tyrosine-phosphorylated
FAK, or a polyclonal FAK antibody, to detect total FAK. Glu-
tamate, which has previously been reported to activate FAK and
is toxic to neurons, was also tested in addition as a positive control
(Siciliano et al., 1996).
Figure 9 (bottom panel) shows that FAK in untreated neurons
(control) was modestly tyrosine phosphorylated, but that FAK in
cultures treated with A25–35 or glutamate displayed an increased
phosphotyrosine content. Pretreatment with LY 294002 or PP2
prevented the A-stimulated increase in FAK tyrosine phosphor-
ylation. PD 98059 and lithium chloride failed to prevent the
A-stimulated increase in FAK tyrosine phosphorylation over
Figure 8. The rate of A-induced FAK activation is similar in primary
rat brain cortical cultures and primary human brain cortical cultures. A, B,
Western blots with 4G10 of protein immunoprecipitated with anti-FAK
polyclonal antibody from cell lysates of 7-d-old primary rat cortical
cultures (A) and of 14-d-old human cortical cultures (B). Shown are
untreated cultures (lane 1) and cultures treated with A25–35 (10 M) for
1 min (lane 2), 2 min (lane 3), 5 min (lane 4 ), and 10 min (lane 5). C,
Western blot with 4G10 of protein immunoprecipitated with anti-FAK
polyclonal antibody from cell lysates of control 7-d-old primary rat cor-
tical cultures left untreated or treated for 5 min with 10 M A25–35 or 10
M A1–42 as indicated. Apparent molecular mass (kDa) is indicated on
the lef t.
Figure 9. PI3-kinase and Fyn are involved in A-induced FAK activa-
tion. Shown are Western blots with 4G10 (bottom panel ) and polyclonal
antibody to FAK (top panel ) of protein immunoprecipitated with anti-
FAK polyclonal antibody from cell lysates of 7-d-old primary rat brain
cortical cultures. Cultures that had been pretreated with LY 294002 (LY ),
PD 98059 (PD), bis-indolylmaleimide (Bis), lithium (Li), or PP2 or left
untreated as outlined in Materials and Methods were either harvested
without further treatment (C) or treated with A25–35 (10 M) for 5 min
(A); a further culture was treated with glutamate (1 mM) alone for 1 hr
(G). Apparent molecular mass (kDa) is indicated on the lef t.
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untreated levels, suggesting that any activation of MAP kinase or
GSK-3 by A occurs downstream of FAK signaling or through an
independent pathway. The inability of bis-indolylmaleimide to
inhibit A-stimulated FAK phosphorylation suggests that FAK
activation under these conditions is not a PKC-dependent mech-
anism, in contrast to FAK activation in response to glutamate or
acetylcholine (Slack, 1998; Tang et al., 1999). Figure 9 (top panel)
shows that the increases in tyrosine phosphorylation observed
under the different conditions was not caused by an increase in the
levels of FAK that were immunoprecipitated. The ability of both
LY 294002 and PP2 to prevent the A-induced FAK phosphor-
ylation suggests that both Fyn and PI3-kinase may be involved in
FAK activation. Both Fyn and PI3-kinase can associate with FAK
through their SH2 domains when FAK is phosphorylated at its
autophosphorylation site, Tyr397 (Cobb et al., 1994; Chen et al.,
1996). The ability of LY 294002 to prevent the A-stimulated
increase in FAK tyrosine phosphorylation suggests that both
PI3-kinase and Fyn may be involved in FAK activation, either
through direct binding of their SH2 domains to FAK or through
SH3 domain interactions between PI3-kinase and Fyn (Renzoni
et al., 1996; Wellbrock and Schartl, 2000). In addition, pretreat-
ment of cultures with the calcium chelator EGTA failed to pre-
vent the A-induced FAK tyrosine phosphorylation (data not
shown).
Inhibitors of FAK tyrosine phosphorylation prevent
A-induced ERK2 activation in primary
neuronal cultures
It has previously been reported that A can stimulate the MAP
kinase signaling pathway involving activation of ERK1 and
ERK2. Because FAK in certain cellular systems has been re-
ported to be upstream of MAP kinase, we investigated the pos-
sibility that ERK1 and ERK2 activation in response to A25–35
treatment is also induced by FAK in neurons. Western blots of rat
neuronal cultures with a non-phosphorylation-dependent mono-
clonal antibody to ERK1 and ERK2 showed that the majority of
MAP kinase was represented by ERK2 (Fig. 10A, top panel).
Treatment of rat neuronal cultures with A25–35 for 5–60 min
caused a sustained increase in the activation of ERK2 as detected
by monoclonal antibodies to the dually phosphorylated threonine-
202 and tyrosine-204 epitope (Fig. 10A, lane 2–5). No activation
of ERK1 was detected, albeit the level of ERK1 was much lower
than ERK2. Pretreatment of cultures with the compounds PD
98059 (Fig. 10A, lanes 8 and 9) or LY 294002 (lanes 10 and 11)
and harvesting without further treatment or with subsequent
exposure to A25–35 for 5 min prevented any A-induced increase
in ERK2 activity without affecting the total ERK protein levels.
Pretreatment with PP2 for 18 hr apparently reduced the total
levels of ERK protein (Fig. 10A, lanes 6 and 7) and also inhibited
A-induced ERK2 activation by 50% (lane 7). Figure 10B shows
the relative amounts of active ERK found in each sample. Taken
together, the results suggest that A activates ERK2 in a MEK-
dependent manner and that ERK activation is downstream of
FAK tyrosine phosphorylation and PI3-kinase and Fyn.
DISCUSSION
The importance of A deposition in the brain in AD is strongly
implicated from genetic studies. All three genes, -amyloid pre-
cursor protein, presenilin 1, and presenilin 2, now known to cause
AD have been shown to cause an increase in A production or an
increase in the ratio of A42/A40, both of which drive aggrega-
tion (Scheuner et al., 1996; Citron et al., 1997). Possession of one
or two E4 alleles of apolipoprotein E also results in increased A
deposition in the brain before clinical symptoms arise (Polvikoski
et al., 1995). It is now generally accepted that deposition of
diffuse deposits of A in the brain is an early event in the
development of AD, and neurotoxicity of A is well established
in in vitro models. There is still a lack of agreement on the
physical nature of the neurotoxic form of A, but fibrils repro-
ducibly damage cultured neurons, although the mechanisms lead-
ing to cell death are not established and reports are often con-
tradictory (Abe and Saito, 2000; Marin et al., 2000; Troy et al.,
2000). The early deposition of A in the pathogenic sequence
emphasizes the importance of elucidating the initial response of
neurons to A fibrils.
Here we confirm that A-derived neurotoxicity in culture is
slow, in agreement with earlier observations (Behl et al., 1994;
Estus et al., 1997; Abe and Saito, 2000; Greeve et al., 2000). Cell
death could not be detected before 24 hr, with a rise in caspase
activity concomitant with LDH release and with complete cell
death in cultures occurring slowly over 96 hr. This is similar to
reported glutamate-induced excitotoxic mechanisms, in which a
marked increase in LDH release in response to glutamate was
measured only after 18–24 hr (Gray and Patel, 1995). However,
glutamate does induce early and irreversible changes before cell
death, in particular Ca2 influx (Randall and Thayer, 1992),
membrane depolarization, and activation of postsynaptic cell
membrane receptors with subsequent opening of ion channels,
resulting in a disturbed intracellular ionic environment, which
then inevitably results in cell death (Rothstein, 1996). We there-
fore looked for early responses to A because they too may be the
critical events in neurotoxicity.
Here we report a rapid and somewhat transient rise in tyrosine
phosphorylation of cellular and cytoskeletal proteins in response
Figure 10. A-induced ERK phosphorylation is downstream of FAK
activation. A, Western blots of RIPA buffer lysates from control 7-d-old
primary rat cortical cultures (lane 1) and cultures treated with A (10 M)
and harvested after 5 min (lane 2), 10 min (lane 3), 30 min (lane 4 ), 60 min
(lane 5), with PP2 alone (30 M) for 18 hr (lane 6 ), A25–35 for 5 min in
culture pretreated with PP2 (lane 7 ), PD 98059 alone (lane 8), A25–35 for
5 min in culture pretreated with PD 98059 (lane 9), LY 294002 alone (lane
10), and A25–35 for 5 min in culture pretreated with LY 294002 (lane 11).
Top panel blot was probed with monoclonal antibody MK12 to ERK;
bottom panel blot was probed with a monoclonal antibody E10 to phos-
phorylated ERK1 ( p44 ) and ERK2 ( p42). B, Quantification of ERK
kinase phosphorylation of the experiments shown in A. The activity, as
indicated numerically beneath the abscissa, is expressed relative to the
control (0 min) that was normalized to 1.
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to both A25–35 and A1–42. The shorter A25–35 was shown to be
more potent than the full-length A1–42 at eliciting an increase in
tyrosine phosphorylation, consistent with previously reported
findings (Varadarajan et al., 2001). The peak increase in tyrosine
phosphorylation was variable, usually being slower in human
neuronal cultures, but precise measurement over short times in
this type of cellular response is problematic. Calcium ions were
not required for the phosphorylation of FAK in response to
A25–35. Previous reports of Ca
2 influx in A-induced cell death
suggest that parallel pathways may be activated in response to A
(Luo et al., 1995; Ekinci et al., 1999; MacManus et al., 2000).
Tyrosine phosphorylation changes often serve to activate down-
stream serine/threonine kinases. The response involved Fyn but
not Src and an activation of FAK and increased association of
FAK with Fyn. These changes are similar to activation of FAK
and Fyn in other cell signaling systems such as integrin signaling.
Other workers have reported tyrosine kinase activation in micro-
glial cultures using higher concentrations of A (50 M), but we
now show that this occurs in neurons in response to 10 M
A25–35 (McDonald et al., 1998). Fyn activation is likely to be
important in A neurotoxicity because Fyn knock-out mice are
reported to be resistant to ADDL toxicity (Lambert et al., 1998).
MAP kinase has previously been reported to be activated in
microglial and THP1 monocyte cultures after administration of
high concentrations of A (Combs et al., 1999); however, the
activation was transient. Now we show that ERK activation is
rapid and sustained and that this is consistent with it being
downstream of FAK association with Fyn. Furthermore, in our
neuronal cultures, PI3-kinase appears to be required for ERK
activation in response to A treatment. This is consistent with
previously reported studies in which inhibition of PI3-kinase
blocked the activation of ERK2 by integrin in fibroblast cell lines
(King et al., 1997; Finkelstein and Shimizu, 2000).
Tau has been shown to be tyrosine phosphorylated in COS7
cells doubly transfected with Fyn and tau (Lee et al., 1998). We
therefore investigated whether tau is tyrosine phosphorylated in
response to A treatment and found that both tau and most likely
MAP2c are tyrosine phosphorylated in neurons and that the
kinetics of tyrosine phosphorylation mimic the kinetics of FAK
activation and FAK/Fyn complex formation. Furthermore, the
ability of PP2 to prevent the A-induced tyrosine phosphoryla-
tion of tau and MAP2c strongly suggests that tau and MAP2c are
indeed substrates of Fyn in the response to A. It was therefore
important to search for evidence of tyrosine phosphorylation of
cytoskeletal proteins in AD brain, and we discovered that PHF-
tau is indeed tyrosine phosphorylated. On the other hand, we
could not demonstrate tyrosine phosphorylation of normal adult
brain tau, although fetal brain tau has a low level of tyrosine
phosphorylation. Thus, it might be that the tyrosine phosphory-
lation of PHF-tau is another example of the phosphorylation state
mimicking the fetal phosphorylation of tau (Kanemaru et al.,
1992; Bramblett et al., 1993; Brion et al., 1993b; Goedert et al.,
1993; Watanabe et al., 1993). Further work needs to be done to
establish whether this tyrosine phosphorylation may trigger ag-
gregation of tau to produce PHF-tau and whether it influences
the phosphorylation of tau by serine/threonine protein kinases. It
is also of interest to determine whether all or only some of the
tyrosine residues in tau are phosphorylated, and so far using a
specific antibody we have shown that tyrosine 29 is phosphory-
lated in human tau in response to A exposure and in PHF-tau.
However, the difference in the labeling pattern of PHF-tau with
this antibody and 4G10 suggests that there may be heterogeneity
of tyrosine phosphorylation in PHF-tau. We also had to enrich
the PHF-tau fraction to obtain labeling with phosphotyrosine-
specific antibodies, and not all cases of AD brain showed evidence
of tyrosine phosphorylation of PHF-tau. This may well be attrib-
utable to the more labile nature of tyrosine phosphorylation
compared with serine and threonine phosphorylation.
FAK levels in the adult brain are found to be at their highest in
the cerebral cortex and hippocampus (Burgaya et al., 1995). FAK
serves as a regulated adaptor protein, recruiting other proteins by
autophosphorylation of its tyrosine397 residue, a high-affinity
binding site for SH2 domains of Fyn, Src, and PI3-kinase (Chen
and Guan, 1994; Cobb et al., 1994; Schaller et al., 1994). Binding
of these kinases can in turn enable them to phosphorylate ty-
rosine residues in the C-terminal region of FAK and also other
cytoskeletal proteins associated with FAK. This is followed by
recruitment of other proteins, resulting in the formation of large
multimolecular structures capable of triggering a number of dif-
ferent signaling pathways.
The rapid changes reported here of FAK and Fyn association
with increased tyrosine phosphorylation of FAK, with ERK ac-
tivation, and elevated tyrosine phosphorylation of cytoskeletal
proteins, all preceded measurable neuronal death. The activation
of Fyn/FAK/PI3-kinase/MAP kinase is associated with protec-
tive (anti-apoptotic) signaling systems under normal physiological
conditions, and all have been reported to be activated by A in
different cell systems (Klinghoffer et al., 1999; Schaeffer and
Weber, 1999; Sonoda et al., 1999; Lee and States, 2000). We
suggest that there may be an incomplete mimicking of positive
trophic signaling and that the full set of downstream changes are
not activated, and hence A induces an abortive response that
then leads to cell death.
The dual role of FAK in normal physiological and pathological
processes highlights its importance as a convergence point in
divergent signaling pathways. Ultimately the nature and compo-
sition of the multimolecular complexes that are formed underly
the physiological effects of FAK activation. Increased tyrosine
phosphorylation of FAK provides a mechanism by which A can
be coupled to signal transduction pathways exerting a major
influence on cell fate decisions. Elucidation of the components of
the multimolecular complexes and signaling pathways is an im-
portant step in understanding A-induced neuronal toxicity.
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